Shots:
PharmaShots has compiled a list of US FDA-approved drugs in the month of August 2024
The US FDA has approved a total of 7 new drugs including 4 new molecular entities and 3 biologics leading to the treatments for patients and advances in the healthcare industry
The major highlighted drug was Johnson & Johnson’s Rybrevant plus Lazcluze…
Shots:
The US FDA has approved J&J’s Rybrevant + Lazcluze as a 1L treatment for LA/metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations
The approval was based on the P-III (MARIPOSA) assessing Rybrevant + lazertinib vs osimertinib and lazertinib alone in 1074 patients
The study reached its 1EP and 2EPs…

